Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation

Transplant Proc. 1999 May;31(3B Suppl):19S-21S. doi: 10.1016/s0041-1345(99)00097-4.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / economics
  • Antilymphocyte Serum / therapeutic use
  • Basiliximab
  • Cost-Benefit Analysis*
  • Daclizumab
  • Graft Rejection / drug therapy
  • Graft Survival
  • Humans
  • Immunoglobulin G / economics
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / economics*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / economics*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / economics
  • Mycophenolic Acid / therapeutic use
  • Recombinant Fusion Proteins*
  • Renal Dialysis / economics
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Daclizumab
  • Mycophenolic Acid